Patients Clinical Trial

Recent News

08/29/2014
New Clinical Data Highlighting Safety and Efficacy of EndoBarrierĀ® Therapy Presented at the 19th World Congress of International Federation for the Surgery of Obesity and Metabolic Disorders
Read More

08/28/2014
GI Dynamics, Inc. Announces the Appointment of Medical Device Industry Veteran Michael D. Dale as President & Chief Executive Officer
Read More

08/07/2014
GI Dynamics to Present at the 34th Annual Canaccord Genuity Growth Conference
Read More


EndoBarrier® is indicated to treat patients with type 2 diabetes and/or obesity for 12 months.
EndoBarrier® has received regulatory approval and is commercially available for use in select international markets.
EndoBarrier® is not approved for sale in the United States and is considered investigational.
CAUTION: INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL (UNITED STATES) LAW TO INVESTIGATIONAL USE